Lenz Therapeutics received FDA approval for its presbyopia treatment, aceclidine-based eye drops, set to launch in the US next quarter. The new non-invasive option targets a largely underserved market, distinguishing Lenz as a small San Diego-based biotech with a focused ophthalmic portfolio. The approval represents a significant milestone given the competitive and challenging nature of the presbyopia market in biopharma.